PMID- 32070162
OWN - NLM
STAT- MEDLINE
DCOM- 20201130
LR  - 20201130
IS  - 1532-2513 (Electronic)
IS  - 0892-3973 (Linking)
VI  - 42
IP  - 2
DP  - 2020 Apr
TI  - Combination of Sarsasapogenin and Fluticasone attenuates ovalbumin-induced airway 
      inflammation in a mouse asthma model.
PG  - 128-137
LID - 10.1080/08923973.2020.1728541 [doi]
AB  - Objective: Asthma is a very common airway inflammatory disease for which the 
      existing drug therapy options are insufficient. In this study, we explored the 
      mechanisms underlying the anti-inflammatory potential of Sarsapogenin (SG) and 
      its combination with Fluticasone (FC) in ovalbumin (OVA)-induced allergic asthma 
      in mice.Methods: In a standard experimental model, asthma in mice was sensitized 
      and challenged by OVA. The mice were treated with SG and SG + FC during OVA 
      challenge. At the completion, lung weight, inflammatory cell count in 
      bronchoalveolar lavage fluid (BALF), serum cytokines levels, immunoglobulin E 
      (IgE) levels, lung nitrate/nitrite (NO) levels, and lung tissue oxidative stress 
      biomarkers were determined. Histopathological evaluation of the lung tissue was 
      also performed.Key findings: Treatment of mice with SG and SG + FC combination 
      intensely diminished the trafficking of total and differential inflammatory cells 
      count into BALF. SG and SG + FC administration significantly reduced the 
      production of inflammatory cytokines, serum IgE levels and restoration of 
      antioxidant stress markers. Histopathological analysis of lung samples 
      effectually weakened bronchial inflammation and mucus production in the lung with 
      a significant reduction in inflammation and mucus score.Conclusion: Our study 
      results suggested that SG and SG + FC effectively reduced allergic airway 
      inflammation via inhibiting pro-inflammatory cytokines, NO expressions and 
      oxidative stress parameters. So, it could be used as a therapeutic potential 
      agent for the treatment of asthma by decreasing its dose in combination with FC 
      to avoid the chronic adverse effects of FC.
FAU - Ingawale, Deepa K
AU  - Ingawale DK
AD  - Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed 
      University, Pune, India.
FAU - Mandlik, Satish K
AU  - Mandlik SK
AD  - Sinhgad College of Pharmacy, Pune, India.
FAU - Patel, Snehal S
AU  - Patel SS
AD  - Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, 
      India.
LA  - eng
PT  - Journal Article
DEP - 20200218
PL  - England
TA  - Immunopharmacol Immunotoxicol
JT  - Immunopharmacology and immunotoxicology
JID - 8800150
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Cytokines)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Spirostans)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 9006-59-1 (Ovalbumin)
RN  - CFS802C28F (sarsasapogenin)
RN  - CUT2W21N7U (Fluticasone)
SB  - IM
MH  - Animals
MH  - Anti-Asthmatic Agents/administration & dosage/*therapeutic use
MH  - Asthma/blood/*drug therapy/immunology
MH  - Cytokines/metabolism
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Drug Therapy, Combination
MH  - Drugs, Chinese Herbal/administration & dosage/*therapeutic use
MH  - Female
MH  - Fluticasone/administration & dosage/*therapeutic use
MH  - Immunoglobulin E/blood
MH  - Lung/*drug effects/immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Ovalbumin/immunology
MH  - Oxidative Stress/drug effects/immunology
MH  - Spirostans/administration & dosage/*therapeutic use
OTO - NOTNLM
OT  - Allergic asthma
OT  - Fluticasone
OT  - Sarsapogenin
OT  - histopathology
OT  - ovalbumin
OT  - pro-inflammatory cytokines
EDAT- 2020/02/20 06:00
MHDA- 2020/12/01 06:00
CRDT- 2020/02/20 06:00
PHST- 2020/02/20 06:00 [pubmed]
PHST- 2020/12/01 06:00 [medline]
PHST- 2020/02/20 06:00 [entrez]
AID - 10.1080/08923973.2020.1728541 [doi]
PST - ppublish
SO  - Immunopharmacol Immunotoxicol. 2020 Apr;42(2):128-137. doi: 
      10.1080/08923973.2020.1728541. Epub 2020 Feb 18.